Silent crisis of venous care in UK
BMJ 2024; 384 doi: https://doi.org/10.1136/bmj-2023-078321 (Published 12 January 2024) Cite this as: BMJ 2024;384:e-078321- Bruce Campbell, honorary consultant1,
- Daniel Carradice, senior lecturer
- 1Royal Devon University Healthcare Trust, Exeter, UK
- 2Hull York Medical School, Hull, UK
- Correspondence to: B Campbell bcam13wr@gmail.com
High quality evidence clearly supports the treatment of common venous diseases. Treatment of symptomatic varicose veins improves quality of life and is highly cost effective,1234 while early treatment of venous leg ulcers speeds healing, reduces recurrence, and potentially reduces costs.5678 Despite this strong evidence, and National Institute for Health and Care Excellence (NICE) guidance recommending referral of people with symptomatic primary or recurrent varicose veins,2 access to treatment for symptomatic varicose veins is restricted in much of the UK, and people who develop leg ulcers experience delay in getting the treatment they need for underlying venous disease.910
Preventing and treating leg ulceration is perhaps the most pressing issue. The importance of early referral and specialist treatment was highlighted in the 2019 report of the All Party Parliamentary Committee on Vascular and Venous Disease, Venous Leg Ulcers: a Silent Crisis.10 Community treatment of venous leg ulcers costs the NHS £1bn-£2bn annually, much of which could be saved by correcting …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.